Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC2 | Q92769 | 1/20 | 0.64 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.64 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 1/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.61 |
| ▸ | HTT | P42858 | 2/20 | 0.59 |
| ▸ | TSHR | P16473 | 2/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | PLK1 | P53350 | 4/20 | 0.57 |
| ▸ | POLB | P06746 | 2/20 | 0.57 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | CES2 | O00748 | 1/20 | 0.54 |
| ▸ | CES1 | P23141 | 1/20 | 0.54 |
| ▸ | CA2 | P00918 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1132053 | 0.94 | HDAC2 (0.57) | HDAC2HDAC8HDAC6ALDH1A1KDM4E | |
| SCHEMBL28680084 | 0.87 | ALDH1A1 (0.55) | HDAC2HDAC8HDAC6ALDH1A1KDM4E | |
| SCHEMBL250247 | 0.87 | HDAC6 (0.80) | HDAC2HDAC8HDAC6ALDH1A1HTT | |
| SCHEMBL15047786 | 0.85 | MAPT (0.67) | ALDH1A1KDM4ELMNAMAPTL3MBTL1 | |
| SCHEMBL13273458 | 0.82 | ALDH1A1 (0.57) | ALDH1A1KDM4ELMNAMAPTL3MBTL1 | |
| SCHEMBL7042272 | 0.82 | POLB (0.63) | HDAC2ALDH1A1KDM4ELMNAMAPT | |
| SCHEMBL3912992 | 0.81 | POLB (0.62) | HDAC2ALDH1A1KDM4ELMNAMAPT | |
| SCHEMBL28959084 | 0.81 | MAPT (0.61) | ALDH1A1KDM4ELMNAMAPTL3MBTL1 | |
| SCHEMBL15545731 | 0.81 | HDAC8 (0.64) | HDAC2HDAC8HDAC6ALDH1A1HTT | |
| SCHEMBL16198923 | 0.80 | HDAC6 (0.70) | HDAC2HDAC8HDAC6HTTTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 287 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2097379-A1 | CARBOXAMIDE DERIVATIVES AS ION CHANNEL MODULATORS | Wyeth a Corporation of the State of Delaware (US) | 2009-09-09 | — | — | EP | claimed |
| WO-2008073936-A1 | CARBOXAMIDE DERIVATIVES AS ION CHANNEL MODULATORS | WYETH (US) | 2008-06-19 | — | — | WO | claimed |
| CN-120004754-A | Preparation method of high-purity N-methyl halogenated benzamide | 福州大学 | 2025-05-16 | — | — | CN | disclosed |
| WO-2025073702-A1 | PROCESS FOR PREPARING AROMATIC AMINES FROM ARYL CHLORIDES | BASF SE (DE) | 2025-04-10 | — | — | WO | disclosed |
| WO-2024086767-A2 | GLYCAN CONJUGATE COMPOSITIONS AND METHODS | GANNA BIO, INC. (US) | 2024-04-25 | — | — | WO | disclosed |
| US-20230301984-A1 | CYCLIC COMPOUNDS FOR USE IN TREATING RETINAL DEGENERATION | THE USA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2023-09-28 | — | — | US | disclosed |
| WO-2023144450-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF CANCER AND INFLAMMATORY CONDITIONS | OULUN YLIOPISTO (FI) | 2023-08-03 | — | — | WO | disclosed |
| US-20230203030-A1 | COMPOUNDS AND METHODS FOR THE ENHANCED DEGRADATION OF TARGETED PROTEINS | ARVINAS OPERATIONS, INC. | 2023-06-29 | — | — | US | disclosed |
| CN-107162928-B | Halogenated analogs of anti-fibrotic agents | 塞尔塔医疗有限公司 | 2022-03-11 | — | — | CN | disclosed |
| US-20210355135-A1 | P38ALPHA MITOGEN-ACTIVATED PROTEIN KINASE INHIBITORS | GEN1E LIFESCIENCES INC. | 2021-11-18 | — | — | US | disclosed |
| EP-2772480-B2 | HIV REPLICATION INHIBITOR | SHIONOGI & CO (JP) | 2020-12-09 | — | — | EP | disclosed |
| US-4097489-A | PROSTAGLANDINS | THE UPJOHN COMPANY (US) | 1978-06-27 | — | — | US | disclosed |
| US-4052382-A | 1-PHENYL-3-AZACARBOCYCLIC-UREAS | STERLING DRUG INC. (US) | 1977-10-04 | — | — | US | disclosed |
| US-4028381-A | ANTIANXIETY AND ANTIDEPRESSANT AGENTS | CIBA-GEIGY CORPORATION (US) | 1977-06-07 | — | — | US | disclosed |
| US-4026938-A | 1-Phenyl-3-azacarbocyclic-ureas | STERLING DRUG INC. (US) | 1977-05-31 | — | — | US | disclosed |
| US-4022801-A | ANTIANXIETY AND ANTIDEPRESSANTS | CIBA-GEIGY CORPORATION (US) | 1977-05-10 | — | — | US | disclosed |
| US-4022800-A | ANTIANXIETY AND ANTIDEPRESSANTS | CIBA-GEIGY CORPORATION (US) | 1977-05-10 | — | — | US | disclosed |
| US-3963748-A | 1-Phenyl-3-azacarbocyclic-ureas | STERLING DRUG INC. (US) | 1976-06-15 | — | — | US | disclosed |
| US-3959269-A | TRANQUILIZERS, SEDATIVES | SANDOZ, INC. (US) | 1976-05-25 | — | — | US | disclosed |
| US-3944570-A | ANTIINFLAMMATORY | SANDOZ, INC. (US) | 1976-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210355135-A1 | P38ALPHA MITOGEN-ACTIVATED PROTEIN KINASE INHIBITORS | MAPKAPK2, MAPK1, MAPK8 | HDAC2 1728/4885HDAC8 643/4885HDAC6 558/4885 |
| US-20230301984-A1 | CYCLIC COMPOUNDS FOR USE IN TREATING RETINAL DEGENERATION | ALDH1A2, PDE6D, PDE6C | HDAC2 263/4885HDAC8 95/4885HDAC6 402/4885 |
| US-20230203030-A1 | COMPOUNDS AND METHODS FOR THE ENHANCED DEGRADATION OF TARGETED PROTEINS | VHL, MDM2, XIAP | HDAC2 1969/4885HDAC8 2117/4885HDAC6 363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.